Contact Information: Contacts: Investor Relations Leslie Wolf-Creutzfeldt T: 646-284-9472 E: lcreutzfeldt@hfgcg.com Media Relations Ivette Almeida T: 646-284-9455 E: ialmeida@hfgcg.com
Prana to Present at Rodman & Renshaw 10th Annual Healthcare Conference
| Source: Prana Biotechnology
MELBOURNE, AUSTRALIA--(Marketwire - October 28, 2008) - Prana Biotechnology Limited (NASDAQ : PRAN ) (ASX : PBT ), a biopharmaceutical company focused on the research and
development of treatments for neurodegenerative disorders, today announced
that the Company is scheduled to present at the Rodman & Renshaw 10th
Annual Global Healthcare Conference, on November 10, in New York City.
Dr. Rudolph Tanzi, co-founding scientist of Prana, will give a presentation
on November 10, at 9:55 a.m. EST on the Company's lead product, PBT2, which
has completed its Phase IIa clinical trial for Alzheimer's disease. Dr.
Tanzi will also provide an update on the Company's pipeline development.
The Conference will feature innovative growth companies and investors
interested in such companies and will focus on firms within the Life
Science, Energy, and Natural Resources sectors, as well as firms based in
promising Emerging Markets. Last year's conference, which focused on Life
Science firms, attracted more than 2,500 investors and industry attendees
and included presentations by more than 350 companies.
About Rodman & Renshaw, LLC
Rodman & Renshaw, LLC is a full service investment bank dedicated to
providing investment banking services to companies that have significant
recurring capital needs due to their growth and development strategies,
along with research and sales and trading services to investor clients that
focus on such companies. Rodman is a leading investment banking firm with
particular emphasis on "essential" industries with significant capital
needs, including health care (especially life science), energy (especially
upstream oil and gas), ferrous and non-ferrous metals, shipping, and
natural resources, as well as a leader in the PIPE (private investment in
public equity) and RD (registered direct placements) transaction markets.
About Prana Biotechnology Limited
Prana Biotechnology was established to commercialize research into
Alzheimer's disease and other major age-related neuro-degenerative
disorders. The company was incorporated in 1997 and listed on the
Australian Stock Exchange in March 2000 and listed on NASDAQ in September
2002. Researchers at prominent international institutions including the
University of Melbourne, The Mental Health Research Institute and
Massachusetts General Hospital, a teaching hospital of Harvard Medical
School, discovered Prana's technology.
For further information, please visit our web site at www.pranabio.com.
Forward-Looking Statements
This press release contains "forward-looking statements" within the meaning
of section 27A of the Securities Act of 1933 and section 21E of the
Securities Exchange Act of 1934. The Company has tried to identify such
forward-looking statements by use of such words as "expects," "intends,"
"hopes," "anticipates," "believes," "could," "may," "evidences" and
"estimates," and other similar expressions, but these words are not the
exclusive means of identifying such statements. Such statements include,
but are not limited to any statements relating to the Company's drug
development program, including, but not limited to the initiation, progress
and outcomes of clinical trials of the Company's drug development program,
including, but not limited to, PBT2, and any other statements that are not
historical facts. Such statements involve risks and uncertainties,
including, but not limited to, those risks and uncertainties relating to
the difficulties or delays in financing, development, testing, regulatory
approval, production and marketing of the Company's drug components,
including, but not limited to, PBT2, the ability of the Company to procure
additional future sources of financing, unexpected adverse side effects or
inadequate therapeutic efficacy of the Company's drug compounds, including,
but not limited to, PBT2, that could slow or prevent products coming to
market, the uncertainty of patent protection for the Company's intellectual
property or trade secrets, including, but not limited to, the intellectual
property relating to PBT2, and other risks detailed from time to time in
the filings the Company makes with Securities and Exchange Commission
including its annual reports on From 20-F and its reports on Form 6-K. Such
statements are based on management's current expectations, but actual
results may differ materially due to various factions including those risks
and uncertainties mentioned or referred to in this press release.
Accordingly, you should not rely on those forward-looking statements as a
prediction of actual future results.